Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had curative treatment (surgery or local ablation) for liver cancer (HCC) and have had no recurrence for more than two years after that treatment
- People who have never received systemic treatment, radiation therapy, or a procedure called trans-arterial chemoembolization for their liver cancer
- People who are older than 20 years of age
- People whose general physical functioning falls within a certain range, meaning they are able to carry out at least some daily activities (this is measured using a scale called the ECOG performance status, scores 0–2; confirm with trial site)
- People who are able to attend scheduled visits and follow the study plan
- People who are willing to sign a written consent form agreeing to take part
Who may not be able to join:
- People who currently have, are suspected of having, or have a history of a cancer where the chance of it coming back within 2 years is 20% or higher
- People who have serious other health conditions where survival is expected to be less than 3 years
- People whose kidneys are not functioning well enough, based on a specific blood test result (confirm with trial site)
- People whose liver disease has reached an advanced stage known as Child-Pugh class C (confirm with trial site)
- People whose situation means a particular liver imaging assessment system (called LI-RADS) cannot be applied — for example, people with a condition called Budd-Chiari Syndrome
- People who have previously had a severe allergic reaction to iodine-based contrast dye used in scans
- People for whom MRI scans are not safe or suitable — for example, those with a cardiac pacemaker or severe claustrophobia that would make completing the study difficult
- People who have any other condition that the trial investigator considers would make participation unsuitable or interfere with completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: So Yeon Kim, MD, PhD, Asan Medical Center
Phone: 82-2-3010-6575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Detection rate (DR) of patients with HCC; False referral rate (FRR) of patients with HCC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.